Agree, but I think IDMI is running neck and neck at the turn.
While INGN is trying to find tissue samples of a long ago unblinded study to support a post hoc subset analysis, IDMI is trying to find still breathing patients on a long abandoned study to hit the secondary OS endpoint on an open lable study.
I honestly am sorry for people who invest in these companies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.